摘要
目的研究静脉注射胚胎干细胞(ESC)对肺纤维化小鼠的治疗作用。方法气管内滴注博来霉素8.5mg/kg制作C57/BL6雌性小鼠的肺纤维化模型。治疗组(n=20)静脉注射S8小鼠ESC,对照组(n=10)注射生理盐水。治疗组又分为单次治疗(n=10)和重复治疗(n=10),两者均在造模后1h静脉注射ESC,重复治疗组在造模后3d再次静脉注射ESC。记录小鼠的生存时间,测定小鼠肺组织的羟脯氨酸含量,肺脏病理学观察炎症状态。利用秩和检验统计3组小鼠生存时间,方差分析3组小鼠肺羟脯氨酸含量的差异。结果接受干细胞治疗后,肺纤维化模型小鼠的生存时间(d)延长,重复治疗组更加明显(对照组、单次治疗组、重复治疗组分别为7.8±2.8、8.4±3.8、13.5±5.6,P<0.01);肺羟脯氨酸含量(μg/mL)降低(对照组、单次治疗组、重复治疗组分别为8.59±1.14、8.23±1.09、5.51±0.39,P<0.01);肺脏病理检查显示肺组织炎症程度降低,结构破坏减轻。结论静脉注射胚胎干细胞可以减轻博来霉素诱导的小鼠肺部炎症和肺纤维化,延长肺纤维化小鼠的生存时间。
Objective To observe ry fibrosis induced by bleomycin. the effect of embryonic stem cell (ESC) on mice model of pulmona- Methods Pulmonary fibrosis was induced in C57/BL6 mice by ble- omycin drop-in to trachea. Intravenous ESC were injected in treatment group 2 and 3 (n = 10 in each group) 1 hour after bleomycin exposure. Sodium chloride was injected in another 10 mice as control in group 1. Mice in group 3 received ESC repeatedly 3 days after bleomycin exposure. The life-spans and hydroxyproline concentrations were examined. The pulmonary inflammation of mice in deferent groups were observed by pathological method. Kruskal-Wallis test and ANOVA were used to tell deference among three groups. Results The life-spans of mice were significantly ( P〈0. 01 ) longer in treatment group 2 (8. 4 ± 3.8 days) and group 3 (13. 5 ± 5.6 days) than those in control group 1 (7. 8 ± 2. 8 days), Meanwhile, the hydroxyproline concentration in group 2 E(8. 23 ± 1.09) μg/mL. and group 3 [(5.51 ± 0. 39) μg/mL] decreased significantly (P〈0. 01 ) than those in control group 1E(8.59 ± 1.14) μg/mL.. Pathological examination showed that inflammation in lungs of treatment group 2 and 3 was less severe than that in control group 1. Conclusions ESC injection may inhibit pulmonary inflammation and fibrosis induced by bleomycin in C57/BL6 mice and can lengthen lifetime of the mice.
出处
《复旦学报(医学版)》
CAS
CSCD
北大核心
2008年第3期418-422,426,共6页
Fudan University Journal of Medical Sciences
基金
上海市科委国际合作项目(044107050)
关键词
特发性肺纤维化
胚胎干细胞
羟脯氨酸
idiopathic pulmonary fibrosis
embryonic stem cell
hydroxyprolin